title: Cardiac amyloidosis: a treatable disease, often overlooked.
authors.affiliation: Cardiac Amyloidosis Program, Brigham and Women’s Hospital, Boston, MA, USA. rfalk@partners.org
authors.forename: Rodney H
authors.initials: RH
authors.lastname: Falk
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D000686:Amyloidosis / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D057911:Angiotensin Receptor Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D004232:Diuretics / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006333:Heart Failure / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D006801:Humans; D000077269:Lenalidomide; D008558:Melphalan / Q000627:therapeutic use; D008875:Middle Aged; D009206:Myocardium / Q000473:pathology; D011228:Prealbumin / Q000235:genetics; D011719:Pyrazines / Q000627:therapeutic use; D012720:Severity of Illness Index; D033581:Stem Cell Transplantation; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000319:Adrenergic beta-Antagonists; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D001897:Boronic Acids; D002121:Calcium Channel Blockers; D004232:Diuretics; D011228:Prealbumin; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D003907:Dexamethasone; D000077269:Lenalidomide; D008558:Melphalan